skip to main content


Evgen is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. We have a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods.  Our pipeline exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

Evgen Pharma Image : About